Company / Operating Income
AGIOS PHARMACEUTICALS, INC. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$472.1M
FY2025
5-year range
-$472.1M / -$335.9M
FY2021-FY2025
Trend
-10.9%
vs FY2024
Sector context
#185 of 204
Health Care
What the data says
Among 204 Health Care companies, AGIOS PHARMACEUTICALS, INC. is in the bottom 9% for operating income. Operating Income has declined for 3 consecutive years, from -$336M in FY2022 to -$472M in FY2025.
Based on SEC 10-K filings.
-$472M in FY2025.
Declined from -$391M to -$472M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 204This company -$472.1M Sector average $107.8M
▼
-538.2% below sector average
Key checks
Key Insights
- AGIOS PHARMACEUTICALS, INC.'s operating income has declined for 3 consecutive years.
- In FY2025, operating income decreased 10.9% year-over-year.
- Ranks #185 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.83 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$472.1M | -10.9% |
| FY2024 | -$425.7M | -8.7% |
| FY2023 | -$391.5M | -16.5% |
| FY2022 | -$335.9M | +11.2% |
| FY2021 | -$378.4M | -4.4% |
| FY2020 | -$362.5M | -14.6% |
| FY2019 | -$316.3M | -57.4% |
| FY2018 | -$201.0M | +37.3% |
| FY2017 | -$320.8M | -59.6% |
| FY2016 | -$201.0M | -416.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026